NL-OMON37356
Completed
Not Applicable
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Study - TIP-study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- advanced tumors for which no treatment options are available
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 13
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age \* 18 years
- •\- Eastern Cooperative Oncology Group (ECOG) performance status of 0\-2
- •\- No radio\-, chemo\- or tumorspecific targeted therapy within the last 4 weeks prior to study entry
- •\- Adequate organ system function
- •\- Patients or partners of patients with childbearing potential should practice adequate contraception (double barrier protection).
- •\- Patient who are lactating should discontinue nursing prior to the first dose and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
Exclusion Criteria
- •\- Current treatment in another therapeutic clinical trial
- •\- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously\-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti\-seizure medication for 6 months prior to first dose of study drug.
- •\- Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
- •\- Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product
- •\- Presence of uncontrolled infection.
- •\- Corrected QT interval (QTc) \> 480 msecs using Bazett\*s formula (QTc \= QT/\*RR)
- •\- History of any one or more of the following cardiovascular conditions within the past 6 months:
- •\* Cardiac angioplasty or stenting
- •\* Myocardial infarction
- •\* Unstable angina
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Will pazopanib dose individualization result in less variability in pazopanib bloodconcentrations between individuals.Cancer,Solid tumorPhase INL-OMON22313eiden University Medical Center13
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208
Completed
Not Applicable
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
Not yet recruiting
Not Applicable
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.rheumatoid arthritisadalimumabtherapeutic drug monitoringNL-OMON29559ReumafondsReade, centrum voor revalidatie en reumatologie102
Recruiting
Phase 3
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyHealth Condition 1: C719- Malignant neoplasm of brain, unspecifiedCTRI/2024/04/066217Amrita School of Pharmacy